Add to Favourites
To login click here
Lantern Pharma, Inc., a clinical-stage biopharmaceutical company, has announced the formation of a wholly-owned subsidiary, Starlight Therapeutics Inc., to develop its drug candidate LP-184 for central nervous system and brain cancer indications. The targeted treatment indications are estimated to represent an annual global market potential of approximately $6.0 billion (USD) and over 500,000 global cases each year.
